Aerie Pharmaceuticals Inc (NASDAQ:AERI) – Equities researchers at Oppenheimer increased their FY2020 earnings estimates for shares of Aerie Pharmaceuticals in a research report issued on Wednesday, March 13th. Oppenheimer analyst E. Rajavelu now forecasts that the company will post earnings of $3.10 per share for the year, up from their previous estimate of $2.99. Oppenheimer currently has a “Buy” rating and a $64.00 price target on the stock.

A number of other brokerages have also issued reports on AERI. ValuEngine lowered Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Cowen reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Wednesday, February 27th. Zacks Investment Research lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. BidaskClub lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, February 26th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $77.36.

Shares of NASDAQ AERI opened at $47.51 on Friday. Aerie Pharmaceuticals has a 1 year low of $32.18 and a 1 year high of $74.75. The stock has a market cap of $2.16 billion, a PE ratio of -10.22 and a beta of 0.97.

Several large investors have recently bought and sold shares of AERI. Bank of Montreal Can boosted its position in shares of Aerie Pharmaceuticals by 40.2% during the fourth quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock worth $38,000 after buying an additional 304 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Aerie Pharmaceuticals by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $99,000 after acquiring an additional 515 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in Aerie Pharmaceuticals by 3.6% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 19,031 shares of the company’s stock valued at $687,000 after purchasing an additional 660 shares during the period. Chartwell Investment Partners LLC raised its stake in Aerie Pharmaceuticals by 3.2% during the 4th quarter. Chartwell Investment Partners LLC now owns 23,735 shares of the company’s stock valued at $857,000 after purchasing an additional 734 shares during the period. Finally, Teachers Advisors LLC raised its stake in Aerie Pharmaceuticals by 1.1% during the 3rd quarter. Teachers Advisors LLC now owns 70,937 shares of the company’s stock valued at $4,366,000 after purchasing an additional 772 shares during the period.

In related news, insider Casey C. Kopczynski sold 11,000 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $46.17, for a total value of $507,870.00. Following the completion of the sale, the insider now directly owns 97,243 shares of the company’s stock, valued at $4,489,709.31. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.53% of the stock is owned by insiders.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Read More: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.